TABLE 3.
Incidence of grade ≥2 and grade ≥3 AEs of interest evaluated in the exposure‐safety analyses
|
Brigatinib (n = 123) |
||
|---|---|---|
| Grade ≥3, n (%) | Grade ≥2, n (%) | |
| Any AE a | 64 (52.0) | – |
| Hypertension | – | 38 (30.9) |
| CPK increase | 32 (26.0) | – |
| Lipase increase | 22 (17.9) | – |
| Rash | – | 15 (12.2) |
| Amylase increase | 10 (8.1) | 24 (19.5) |
| ALT increase | 6 (4.9) | 18 (14.6) |
| AST increase | 5 (4.1) | 10 (8.1) |
| Bradycardia | – | 2 (1.6) |
| Hyperglycemia | – | 2 (1.6) |
| Pulmonary AEs b | – | 2 (1.6) |
Data are reported as the number of patients (%).
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST aspartate aminotransferase; CPK, creatine phosphokinase.
a
Any grade ≥3 AE included CPK, AST, ALT, amylase, lipase, hyperglycemia, hypertension, bradycardia, rash, and pulmonary events.
b
Pulmonary AEs include pneumonitis and interstitial lung disease.